Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Lipid Catabolism01:25

Lipid Catabolism

1.4K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.4K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

6.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.8K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.5K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

634
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
634
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

5.5K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accessibility and harmonization of biochemical tests for diagnosis and monitoring of Porphyrias in the United States: Recommendations by members of the American Porphyrias Expert Collaborative (APEX).

Molecular genetics and metabolism·2026
Same author

Rapidly progressive, infantile lysosomal acid lipase deficiency: Prevalence in the Mizrahi Jewish population.

Molecular genetics and metabolism·2025
Same author

A Prospective, Blinded Study of Symptom Prevalence and Specificity of Porphyrin Precursors in Carriers of Acute Hepatic Porphyria.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Challenges in Gaucher disease: Perspectives from an expert panel.

Molecular genetics and metabolism·2025
Same author

Sengers syndrome caused by biallelic TIMM29 variants and RNAi silencing in Drosophila orthologue recapitulates the human phenotype.

Human genomics·2025
Same author

Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.

Clinical kidney journal·2024

Related Experiment Video

Updated: Apr 23, 2026

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

7.6K

JCL Roundtable: enzyme replacement therapy for lipid storage disorders.

W Virgil Brown1, Robert J Desnick2, Gregory A Grabowski3

  • 1Emory University School of Medicine, 3208 Habersham Rd., NW, Atlanta, GA 30305, USA.

Journal of Clinical Lipidology
|September 20, 2014
PubMed
Summary

Enzyme replacement therapy offers new hope for inherited lipid storage disorders like Gaucher and Fabry disease. This treatment replaces defective enzymes, addressing the root cause of these debilitating conditions.

Keywords:
EnzymesFabry diseaseGaucher diseaseLipid disordersLysosomal diseases

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

7.6K

Related Experiment Videos

Last Updated: Apr 23, 2026

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

7.6K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

7.6K

Area of Science:

  • Biochemistry
  • Genetics
  • Lysosomal Storage Disorders

Background:

  • Inherited lipid storage disorders cause severe organ damage, lifelong morbidity, and early mortality.
  • Examples include Gaucher disease, Fabry disease, and lysosomal acid lipase deficiencies (Wolman disease, cholesteryl ester storage disease).
  • These conditions present significant challenges for patients, families, and healthcare providers.

Purpose of the Study:

  • To discuss the advancements and clinical applications of enzyme replacement therapy (ERT) for inherited lipid storage disorders.
  • To highlight the role of recombinant protein synthesis in developing ERT.
  • To feature insights from leading researchers involved in ERT development and clinical trials.

Main Methods:

  • Utilizing recombinant DNA technology to synthesize therapeutic enzymes.
  • Targeting enzyme delivery to lysosomes, the site of lipid degradation.
  • Clinical trials to evaluate the efficacy and safety of ERT.

Main Results:

  • Enzyme replacement therapy has demonstrated value in treating specific inherited lipid storage disorders.
  • Recombinant enzymes can be synthesized to replace defective ones, addressing the underlying pathophysiology.
  • Successful delivery of enzymes to lysosomes facilitates substrate degradation.

Conclusions:

  • Enzyme replacement therapy represents a significant breakthrough in managing inherited lipid storage disorders.
  • This therapeutic approach offers improved outcomes for patients with conditions like Gaucher and Fabry disease.
  • Ongoing research and development continue to expand the potential of ERT.